“We need to strive to be an easy client. Being an easy client with clear goals and internal alignment is key for successful long-term relationships with CMOs. Equally important is how we manage internally – how we align internally and
“We are seeing a doubling or tripling of applications from the United States. You can really feel that shift already. People have been offered jobs and professorships and are already here in Heidelberg.” Dr. Julia Schaft, Managing Director at BioRN
HHS Secretary’s unprecedented move to terminate 22 federal mRNA contracts sends shockwaves through biotech sector and raises critical questions about U.S. pandemic preparedness The pharmaceutical industry woke up to a fundamentally altered landscape this week as Health and Human Services
“When you are seeing great results in your research lab, you think that everything has been done. But then when you try to humanise your drug, a new adventure starts, because the CMC process is very difficult. In my opinion,
“From Tokyo to Boston, we knew people had to see and feel the future we were building together. That is how you create lasting change.” Amber Meriwether, Director of Corporate Strategy at Astellas Pharma, has orchestrated one of the industry’s
“Current revenue scale is $1.3 billion. We anticipate it will grow to $5 billion, just in five years’ time. We’ve committed to invest about two-thirds of Fujifilm’s entire annual capex in this business.” Toshihisa “Toshi” Iida, Chairman of FUJIFILM Biotechnologies
How Digital Is Your CDMO? Take this quick 5 minute assessment to benchmark your organization’s Digital and AI maturity — and see how you compare with industry peers.
At CDMO Live 2025 a panel of M&A advisors and consultants explored how private equity investment has transformed the contract manufacturing sector, whilst examining current challenges from geopolitical uncertainty to market volatility. The session, sponsored by TH Healthcare & Life
The biologics external manufacturing panel at CDMO Live 2025, sponsored by BSP Pharmaceuticals, brought together industry leaders to tackle the key challenges in scaling biological manufacturing amid geopolitical tensions, capacity constraints and evolving partnership models. The panel featured Olaf Birkenmeier,
At CDMO Live 2025, Elisabeth Stampa (Medicines for Europe), Elena Barboni (Flamma) and Agneta Larhed (RegSmart Life Science) discussed how Europe’s stringent new regulations could reshape the continent’s pharmaceutical manufacturing landscape. Europe’s pharmaceutical manufacturing sector faces an unprecedented challenge as
